Showing 2751-2760 of 20410 results for "".
Use of Wearable Fitness Technology Does Not Improve Weight Loss
https://reachmd.com/programs/the-jama-report/use-wearable-fitness-technology-does-not-improve-weight-loss/8359/A new JAMA study reports that using fitness wearables did not result in more weight loss among a group of obese and overweight young adults.Insights and Updates: New Data on Next-Generation Retinal Treatments
https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/Join our faculty as they discuss the latest clinical and real-world data surrounding faricimab, aflibercept 8 mg, and the PDS with ranibizumab.Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
https://reachmd.com/programs/heart-matters/translating-patisirans-6-minute-walk-test-gains-into-real-life-impact-in-attr-cm/36136/MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
https://reachmd.com/programs/neurofrontiers/program-name/36357/Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
https://reachmd.com/programs/neurofrontiers/pregnancy-and-infant-outcomes-in-multiple-sclerosis-findings-from-the-maple-ms-pharmacovigilance-program/36358/ATTR-CM Epidemiology: Prevalence, Incidence, and Recognition Trends
https://reachmd.com/programs/spotlight-attr-cm/attr-cm-epidemiology-prevalence-recognition-trends/60666/Silent Threats in a Pandemic: The Emotional Tolls of Self-Isolation
https://reachmd.com/programs/covid-19-frontlines/silent-threats-pandemic-emotional-tolls-self-isolation/11344/Clinicians at high risk of exposure from COVID-19 are facing difficult choices about how to keep their loved ones safe.Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
https://reachmd.com/programs/project-oncology/dexamethasone-her-2-positive-breast-cancer/48766/Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Case: Implementing ADT Intensification in mHSPC
https://reachmd.com/programs/cme/Case-Implementing-ADT-Intensification-in-mHSPC/57197/Explore individualized treatment intensification, molecular profiling, and adverse event management in metastatic hormone-sensitive prostate cancer.